Physician profile
Gary J Bergman
NPI 1568412005
$307.35
in general payments reported to CMS, 2019-2025
10 companies · $61.81 in 2025
The $61.81 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.78 · 2020: $24.43 · 2021: $23.97 · 2022: $46.41 · 2023: $19.50 · 2024: $81.45 · 2025: $61.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $162.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $62.29 | 2023-2024 | Gemtesa, Myfembree |
| Pfizer INC. | $46.41 | 2022 | |
| Merck Sharp & Dohme LLC | $45.58 | 2024-2025 | Vaxelis, Gardasil 9, Gardasil |
| Kaleo, INC. | $36.94 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $25.70 | 2025 | Neffy |
| Supernus Pharmaceuticals, INC. | $23.97 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.45 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.63 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $13.56 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bergman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.